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Introduction 
Interstitial granulomatous drug reaction (IGDR) is a 
distinct inflammatory reaction of the skin 
characterized by erythematous-to-violaceous 
plaques on the lateral trunk, axillae, buttocks, and 
thighs [1]. We present the first case of IGDR related to 
hydrochlorothiazide (HCTZ), to our knowledge, and 
our approach to management of this condition. 
Hydrochlorothiazide is a thiazide diuretic commonly 
used as a first line treatment for hypertension. 
Hydrochlorothiazide is also used to treat water 
retention in patients with congestive heart failure, 
liver cirrhosis, or kidney disease. Commonly reported 
adverse effects include electrolyte abnormalities, 
orthostatic hypotension, hyperglycemia, and 
photosensitivity [2]. 
 
Case Synopsis 
A 70-year-old man presented with a one-month 
history of an itchy rash distributed over his central 
chest, abdomen, back, arms, face, scalp, and thighs 
that started after returning from Florida. On 
examination, he had symmetrically distributed 
salmon pink-to-reddish indurated polygonal 
papules, some with central umbilication, coalescing 
into plaques with psoriasiform scales on his torso 
and limbs (Figure 1). His past medical history was 
significant for well-controlled hypertension, 
hyperlipidemia, GERD, and COPD. His medications 
included citalopram, HCTZ, atorvastatin, amiloride, 
and rabeprazole. He had no history of skin disease, 
rheumatoid arthritis, systemic vasculitis, or other 
autoimmune conditions. Complete blood count and 
urinalysis were normal and he tested negative for 
ANA, ENA, ANCAs, HIV, and Hepatitis B/C. A trial of 
prednisone was initiated by his primary care 
physician with no effect. 
Histopathology of punch biopsies taken from 
multiple areas on the chest and limbs, showed 
intense granulomatous inflammation in the upper 
dermis characterized by palisaded granulomas 
centered around a core of necrobiotic collagen  
Abstract 
Interstitial granulomatous drug reaction is a rare 
condition presenting as erythematous-to-violaceous 
plaques on the lateral trunk, axillae, buttocks, and 
thighs. Calcium-channel blockers, angiotensin 
converting enzyme inhibitors, beta-blockers, and 
statins have been described as drugs that can trigger 
interstitial granulomatous drug reaction. We present 
a case of interstitial granulomatous drug reaction 
related to hydrochlorothiazide and our approach to 
management of this condition. The diagnosis was 
confirmed with a skin biopsy and a rechallenge of 
hydrochlorothiazide, which exacerbated the 
patient’s symptoms. The patient improved 
significantly with rigorous photoprotection, 
combination dapsone-alitretinoin therapy, and 
discontinuation of hydrochlorothiazide.  
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mixed with neutrophils and basophilic necrotic 
debris (Figure 2). Special stains for bacteria, fungus, 
and acid-fast mycobacteria were negative. The 
pathology was suggestive of palisaded and 
neutrophilic granulomatous dermatitis but with 
more mucin than usual. Owing to the 
preponderance of neutrophils on pathology, 
dapsone was initiated with modest improvement. 
Over time, he also developed quite significant hand 
dermatitis, and alitretinoin was added. He was noted 
to be extremely photosensitive, with flares occurring 
with each trip to sunny southern climates. His skin 
improved significantly with rigorous 
photoprotection and a combination of dapsone 
100mg daily and alitretinoin 30mg daily but flared 
with tapering of these medications. In consultation 
with his family doctor, HCTZ, rabeprazole, and 
atorvastatin were gradually stopped or replaced. 
After stopping HCTZ, he developed severe 
peripheral edema and thus restarted it, leading to a 
dramatic reappearance of his cutaneous disease 
(Figure 3). Substitution of HCTZ for spironolactone 
allowed clearing of his skin condition without 
subsequent exacerbations. A timeline of our 
patient’s clinical course is shown in Figure 4.  
 
Case Discussion 
Reactive granulomatous dermatitis is a term which 
encompasses palisaded neutrophilic and  
  
Figure 1: Initial patient presentation. A) Clinical photograph 
depicting red psoriasiform scales on the right shoulder. B) Clinical 
photograph showing violaceous plaques over the left anterior 
thigh. 
 
 
Figure 2: Skin biopsy results. A) Low power micrograph 
demonstrating the presence of dense infiltrate spanning the 
dermis. H&E, 40×. B) High power micrograph demonstrating the 
presence of histiocytic inflammation and foci of neutrophilic 
degeneration. H&E, 400×. 
 
Figure 3: Patient presentation after restarting HCTZ. Clinical 
photograph showing pink indurated papules with some central 
umbilication coalescing into plaques.  
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granulomatous dermatitis (PNGD), interstitial 
granulomatous dermatitis (IGD), and interstitial 
granulomatous drug reaction (IGDR). The 
etiopathogenesis is not well understood but it is 
believed to result from immune complex deposition, 
resulting in altered vascular dynamics and 
subsequent collagen degeneration, which triggers 
granulomatous inflammation [3]. Clinical and 
histological features can help differentiate between 
these conditions (Table 1). 
PNGD presents with skin-colored to erythematous 
papules on extensor surfaces with central  
umbilication. However, IGD and IGDR both present 
with a range of cutaneous manifestations including 
erythematous papules, plaques, and ropelike cords 
usually found on the lateral trunk, axillae, thighs, and 
buttocks [1]. IGDR can mimic PNGD and IGD both 
clinically and histologically. IGDR may occur after a 
long delay ranging from 4 weeks to 25 years (mean 5 
years) after starting the culprit medication and 
resolves in 1-40 weeks (mean 8 weeks) after drug 
discontinuation [4]. Common offending medications 
include calcium channel blockers, statins, 
furosemide, beta-blockers, antihistamines, 
angiotensin-converting enzyme inhibitors, TNF  
 
Figure 4: Timeline of clinical course. 
Table 1. Comparison of the three types of reactive granulomatous dermatitides. 
 
Palisaded neutrophilic and 
granulomatous dermatitis 
(PNGD) 
Interstitial granulomatous 
dermatitis (IGD) 
 
Interstitial granulomatous 
drug reaction (IGDR).
Clinical 
Presentation 
Skin-colored to erythematous 
papules on extensor surfaces 
with central umbilication [8] 
 
Various manifestations including 
erythematous papules, plaques, and 
ropelike cords usually found on the 
lateral trunk, axillae, thighs, and 
buttocks [1,9]
Presents similar to IGD 
Pathology 
Intense neutrophilic and 
interstitial histiocytic infiltrate 
along with potential evidence 
of vasculitis [8] 
Diffuse dermal infiltrate of 
lymphocytes, eosinophils, histiocytes 
and necrobiotic collagen [9] 
Vacuolar interface dermatitis, 
atypical lymphocytes, prominent 
eosinophils, a lack of neutrophils 
and minimal collagen 
degeneration [11]
Associations 
Connective tissue diseases 
including rheumatoid arthritis 
(RA), systemic lupus 
erythematosus, and systemic 
vasculitis [8] 
 
RA, seronegative arthritis/ 
polyarthralgia, autoimmune 
thyroiditis, as well as paraneoplastic 
presentations associated with a 
range of solid hematopoietic tumors 
[1]
 
Beta blockers, calcium channel 
blockers, statins, antihistamines, 
NSAIDs, TNF-alpha inhibitors, and 
diuretics [10] 
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inhibitors, and anakinra. Rare causes include 
carbamazepine, diazepam, bupropion, darifenacin, 
sennoside, and ganciclovir [5]. 
Histologically, IGD is characterized by diffuse dermal 
infiltrate of lymphocytes, eosinophils, histiocytes, 
and necrobiotic collagen [6]. In contrast, PNGD has 
an intense neutrophilic and interstitial histiocytic 
infiltrate along with potential evidence of vasculitis. 
Histological features that favor IGDR include 
vacuolar interface dermatitis, a variable amount of 
mucin deposition, atypical lymphocytes, prominent 
eosinophils, a lack of neutrophils, and minimal 
collagen degeneration [7]. 
The diagnosis of reactive granulomatous dermatitis 
necessitates investigations for associated connective 
tissue conditions. PNGD is reported to be associated 
with connective tissue diseases including 
rheumatoid arthritis, systemic lupus erythematosus, 
and systemic vasculitis (particularly granulomatosis 
with polyangiitis). The most common associations 
with IGD are rheumatoid arthritis, seronegative 
arthritis/polyarthralgias, and autoimmune 
thyroiditis; there are also paraneoplastic 
presentations associated with a range of solid and 
hematopoietic tumors [7]. 
Our patient presented with characteristic 
symmetrical erythematous papules and plaques 
over his central chest, abdomen, back, arms, face, 
scalp, and thighs. Extensive testing for connective 
tissue diseases was negative. Our patient’s eruption 
was exquisitely photosensitive and he experienced 
significant exacerbation with sun exposure, which 
has not been previously reported in IGDR. A possible 
explanation is that the causative medication in his 
case was HCTZ, which is a known photosensitizer. 
However, HCTZ has not been previously reported to 
cause a granulomatous reaction. Definitive diagnosis 
of a drug eruption requires rechallenge. Our patient’s 
self-directed reinitiation of HCTZ to treat worsening 
peripheral edema satisfies the rechallenge 
requirement and identified HCTZ as the culprit drug 
causing IGDR. To further support this, discontinuing 
HCTZ led to clearing of his skin condition.  
The most important treatment for IGDR is 
withdrawal of the offending medication. Adjunctive 
therapies with reported efficacy include topical or 
intralesional corticosteroids, dapsone, and 
hydroxychloroquine [3]. For our patient, the 
combination of dapsone, alitretinoin, and rigorous 
photoprotection was effective. 
 
Conclusion 
Our presentation highlights an unusual case of IGDR 
related to HCTZ and associated with significant 
photosensitivity. Treatment with dapsone and 
alitretinoin fully cleared the eruption before we were 
able to identify the causative medication. Full 
resolution occurred with discontinuation of the 
offending medication, HCTZ. 
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